Τίτλος:
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective.?To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism. Design.?Prospective randomised study. Setting. Division of Endocrinology and Human Reproduction, Aristotle University of Thessaloniki. Patients.?Forty-five (45) women with PCOS diagnosed according to the criteria proposed in 1990 by the NIH. Interventions.?Women with PCOS were randomised into three groups, all treated for 6 months: Group A received an OC containing 35 μ g ethinylestradiol plus 2 mg cyproterone acetate, Group B received an OC containing 30 μ g ethinylestradiol plus 3 mg drospirenone and Group C received metformin 850 mg × 2. Main outcome measure(s).?Anti-Müllerian hormone levels were measured by a specific ELISA. Results.?AMH was significantly decreased under treatment with 35 μ g ethinylestradiol plus 2 mg cyproterone acetate (p = 0.002 at 3 months and p < 0.001 at 6 months). Treatment with 30 μ g ethinylestradiol plus 3 mg drospirenone, and treatment with metformin 850 mg × 2 did not significantly affect serum AMH levels. AMH was significantly decreased under OCs treatment compared to metformin 850 mg × 2 (p = 0.005). Conclusion(s).?AMH serum levels were significantly decreased under treatment with 35 μ g ethinylestradiol plus 2 mg cyproterone acetate, due to decrease in androgens and suppression of gonadotropins. © 2010 Informa UK, Ltd.
Συγγραφείς:
Panidis, D.
Georgopoulos, N.A.
Piouka, A.
Katsikis, I.
Saltamavros, A.D.
Decavalas, G.
Diamanti-Kandarakis, E.
Περιοδικό:
Gynecological Endocrinology
Λέξεις-κλειδιά:
androstenedione; cyproterone acetate; drospirenone; ethinylestradiol; follitropin; glucose; hydroxyprogesterone; insulin; luteinizing hormone; metformin; Muellerian inhibiting factor; oral contraceptive agent; prasterone sulfate; prolactin; sex hormone binding globulin; testosterone, adult; androstenedione blood level; anovulation; article; body mass; clinical article; cohort analysis; comparative study; controlled study; enzyme linked immunosorbent assay; female; follitropin blood level; follow up; glucose blood level; human; hyperandrogenism; insulin blood level; luteinizing hormone blood level; menstrual cycle; menstruation; ovary polycystic disease; priority journal; prolactin blood level; prospective study; randomized controlled trial; testosterone blood level; treatment duration, Adolescent; Adult; Androgen Antagonists; Androstenes; Anti-Mullerian Hormone; Blood Glucose; Body Mass Index; Cohort Studies; Contraceptives, Oral, Combined; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Practice Guidelines as Topic; Young Adult
DOI:
10.3109/09513590.2010.507283
